Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Darren Mckerrecher"'
Autor:
Darren A.E. Cross, Philip C. Mack, David R. Gandara, James G. Keck, Rebekah A. Burich, Daniel P. Vang, Mingshan Cheng, Darren McKerrecher, M. Raymond V. Finlay, Richard A. Ward, Daniel J. O'Neill, Maria Emanuela Cuomo, Ludovic Ménard, Anna D. Staniszewska, Jonathan P. Orme, Jonathan W. Riess, Matthew J. Martin, Nicolas Floc'h
Supplementary figure 1: Generation of H2073 ASV and H2073 SVD. Supplementary figure 2: H2073 parental and Ex20Ins are dependent on EGFR for survival in vitro. Supplementary figure 3: Effect of TKI on the Sytox Proliferation of H2073 wt, H2073-SVD and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f56c0e6f4081d567187d483f6041777
https://doi.org/10.1158/1535-7163.22505797
https://doi.org/10.1158/1535-7163.22505797
Autor:
Darren A.E. Cross, Philip C. Mack, David R. Gandara, James G. Keck, Rebekah A. Burich, Daniel P. Vang, Mingshan Cheng, Darren McKerrecher, M. Raymond V. Finlay, Richard A. Ward, Daniel J. O'Neill, Maria Emanuela Cuomo, Ludovic Ménard, Anna D. Staniszewska, Jonathan P. Orme, Jonathan W. Riess, Matthew J. Martin, Nicolas Floc'h
EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non–small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation EGFR inhibitors, and current standard of care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de56d8339b2fdb08f9c7f6a79f45f94b
https://doi.org/10.1158/1535-7163.c.6538186.v1
https://doi.org/10.1158/1535-7163.c.6538186.v1
Autor:
Oliver R. Steward, Thomas A. King, Michael S. Bodnarchuk, Darren Mckerrecher, S. Bagal, Peng Wang, Xuehong Luo
Publikováno v:
Synlett. 31:502-506
An intramolecular oxetane ring-opening was developed, affording novel 2-(hydroxymethyl)-2,3-dihydroimidazo[1,2-c]quinazolines from N-(3-methyloxetan-3-yl)quinazolin-4-amines under mild conditions. The resulting medicinally relevant tricyclic scaffold
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e36b43e4098f0388ed22eb9553388f76
https://doi.org/10.1055/s-0039-1691578
https://doi.org/10.1055/s-0039-1691578
Autor:
Darren Cross, Matthew J. Martin, Carine M. Guérot, Nicolas Floc'h, Clare Gregson, Jonathan P. Orme, Michal Bista, Lin Xue, Xu Li, Amar Rahi, Xiliang Zhao, Richard A. Ward, L. Evans, Gail L. Wrigley, Arash Mosallanejad, Tieguang Yao, Claire McWhirter, David J. Hargreaves, Nicola Colclough, Sue Bickerton, Darren Mckerrecher, Peter Barton, Yang Ye, Yi Liu, Marta Wylot, M. Raymond V. Finlay, Xiaoming Kang, Eva M. Lenz, Daniel O'Neill, Verity Talbot, Olivier Lorthioir, Paul D. Smith
Publikováno v:
Journal of medicinal chemistry. 64(18)
The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including osimertinib, have been approved for cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58199c545ee296c2c44cec7db12bfba5
https://pubmed.ncbi.nlm.nih.gov/34491761
https://pubmed.ncbi.nlm.nih.gov/34491761
Autor:
Vikki Flemington, Stephen Fawell, Nicolas Floc'h, Paul D. Smith, Richard A. Ward, Darren Mckerrecher
Publikováno v:
Chemical reviews. 121(6)
There has been huge progress in the discovery of targeted cancer therapies in recent years. However, even for the most successful and impactful cancer drugs which have been approved, both innate and acquired mechanisms of resistance are commonplace.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089ad7baa69f065f6fa78be4527bb5ba
https://pubmed.ncbi.nlm.nih.gov/32692162
https://pubmed.ncbi.nlm.nih.gov/32692162
Autor:
Daniel P. Vang, Anna Staniszewska, Matthew J. Martin, James G. Keck, Darren Cross, Jonathan W. Riess, Mingshan Cheng, Maria Emanuela Cuomo, M. Raymond V. Finlay, Ludovic Ménard, Rebekah A. Burich, Darren Mckerrecher, Nicolas Floc'h, David R. Gandara, Jonathan P. Orme, Richard A. Ward, Daniel O'Neill, Philip C. Mack
EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non–small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation EGFR inhibitors, and current standard of care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e66e09f91e4ee9b80623cfb56bb2e9
https://europepmc.org/articles/PMC5932243/
https://europepmc.org/articles/PMC5932243/
Autor:
Alan Steven, Darren Mckerrecher
Publikováno v:
ACS Symposium Series ISBN: 9780841233980
ACS Symposium Series
ACS Symposium Series
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0243a11e62361de31d6a2d77bb5afb
https://doi.org/10.1021/bk-2018-1307.ch007
https://doi.org/10.1021/bk-2018-1307.ch007
Autor:
Ahmed F. Abdel-Magid, Jaan A. Pesti, Rajappa Vaidyanathan, Xin Linghu, Nicholas Wong, James F. Blake, John J. Gaudino, John G. Moffat, Steven M. Mennen, John Stellwagen, Ryan D. White, David A. Thaisrivongs, William J. Morris, Jack D. Scott, Harrie J. M. Gijsen, Jinguang Lin, Yannis Houpis, Ling Tong, Joseph A. Kozlowski, Louis-Charles Campeau, Jingjun Yin, Staffan Karlsson, Daniel Pettersen, Henrik Sörensen, Darren McKerrecher, Alan Steven, Fredrik Zetterberg, Carl-Johan Aurell, James W. Leahy, Sriram Naganathan, Denise L. Andersen, Neil G. Andersen, Stephen Lau
Autor:
Stefan Kavanagh, Julian A. Hudson, David S. Clarke, Alison Easter, Paul Schofield, Anne Ertan, Darren Mckerrecher, Hayley S. Brown, Suzanne S. Bowker, James S. Scott, Elizabeth A. Martin, David Laber, Philip A. MacFaul, Per H. Svensson, Joanne Teague, Andrew G. Leach, Kristin Goldberg, Katy J. Brocklehurst
Publikováno v:
Journal of Medicinal Chemistry. 57:8984-8998
Agonism of GPR119 is viewed as a potential therapeutic approach for the treatment of type II diabetes and other elements of metabolic syndrome. During progression of a previously disclosed candidate 1 through mice toxicity studies, we observed tonic-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b741924ba4d25d89fbb217e9b9132a04
https://doi.org/10.1021/jm5011012
https://doi.org/10.1021/jm5011012
Autor:
Nicolas Floch, M. Raymond V. Finlay, Ambra Bianco, Sue Bickerton, Nicola Colclough, Darren A. Cross, Emanuela M. Cuomo, Carine M. Guerot, David Hargreaves, Matthew J. Martin, Darren McKerrecher, Daniel J. O’Neill, Jonathan P. Orme, Amar Rahi, Paul D. Smith, Richard A. Ward
Publikováno v:
Cancer Research. 79:4451-4451
Osimertinib is a next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with activity against both the activating and the ‘gatekeeper’ T790M EGFR mutations. An acquired EGFR C797S mutation has been reported to med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2920b49837b568a691b620d6c71ca95
https://doi.org/10.1158/1538-7445.am2019-4451
https://doi.org/10.1158/1538-7445.am2019-4451